G
laucoma is a progressive optic neuropathy with features similar to nonarteritic anterior ischemic optic neuropathy (NAION), the most common optic neuropathy causing acute vision loss. Glaucoma has an annual incidence rate of 240 per capita, while NAION has an annual incidence of 2.3 per capita among individuals older than 50 years. 1, 2 Early diabetes mellitus (DM)-defined as an absence of clinically visible diabetic retinopathy-may be associated with upregulation and downregulation of intraocular interferon, interleukins, and other cytokines promoting neuroprotection. 3 The initial Ocular Hypertension Treatment Study report documented a protective effect of early DM in glaucoma development, but reanalysis showed no effect. 4, 5 Studies have shown DM to be a risk factor for NAION, but it is possible that early DM could have neuroprotective effects in NAION. Hayreh and Zimmerman 6 had documented less severe visual field loss for diabetic patients with NAION. However, 11% of their participants had juvenile diabetes, 36% had diabetic retinopathy, and the investigators had used manual kinetic perimetry. To discern the role of early DM in NAION, we have studied patients aged 50 years or older without diabetic retinopathy using automated static perimetry.
Methods.
We reviewed the records of all patients with NAION evaluated by the neuro-ophthalmology service between October 1990 and August 2009, after obtaining institutional review board approval. Criteria for NAION were similar to those used in past studies. 
COMMENTS AND OPINIONS

Acupuncture and the Placebo Effect
I
read with interest the article by Zhao et al. 1 The authors say, "We did not include a sham acupuncture group in our study, mainly because of its poor acceptance by patients and their parents, which, in turn, would have substantially increased the difficulty in recruiting patients." Understandably, Chinese parents who believe in acupuncture would not risk their children's vision to sham acupuncture, just to participate in a clinical study. Likewise, many American parents will not risk their children's vision to participate in a study in which there is an even chance they will undergo acupuncture instead of conventional patching. This cultural difference could make reproducing the Chinese study in the United States problematic.
Fortunately, in the absence of a sham acupuncture control group, there remains an indirect approach to evaluating the amblyopia study: review how sham acupuncture has fared in similar studies.
A 2010 position paper from the Center for Inquiry Office of Public Policy says, "It is becoming increasingly clear that the placebo effect accounts for much of the optimistic research on acupuncture published between the 1970s and 1990s. With the development of sham needles during the past decade-needles which retract like stage knives-researchers have since been able to more accurately assess the therapeutic effects of acupuncture. The result has been a complete unraveling of nearly all acupuncture claims.... The bulk of recent research strongly tends towards the hypothesis that acupuncture's positive effects are mainly due to a built-in expectation bias." 2 A wondrous panacea, acupuncture apparently cures every ailment troubling mankind. All over the United States, acupuncturists and others who practice it, such as chiropractors, are advertising improvement rates as high as 95% for macular degeneration, retinitis pigmentosa, glaucoma, and many other retinal and optic nerve conditions. Some of these practitioners apply needles to only the hands and feet; others, to only the ear. 3 A disinterested observer might conclude that if needle placement is immaterial and sham acupuncture works just as well as the real thing, to claim acupuncture comprises a legitimate body of medical knowledge is absurd.
Incidentally, given the sensational publicity in the United States about Oriental medicine's use of acupuncture, that only about 15% to 20% of Chinese patients choose traditional oriental medicine, including acupuncture, over Western medicine may be of interest. 4 In Japan, the number is under 7% on a yearly basis. 5 In addition to their lacking a sham acupuncture control, it troubles me to read the authors have patented their needle placement. Does this mean other researchers must pay a fee to stimulate those "acupoints"? Will stimulating different points be sufficient reason to dismiss future researchers' failure to duplicate the results of this study? Is there any precedent in medical history in which a researcher has patented body parts for proprietary stimulation? If an amblyopic child is missing a hand or leg and thus cannot receive the patented therapy (acupoints hegu and fyang, respectively), does this mean he is doomed to poor vision the rest of his life? †Died March 11, 2011. 
